U.S. body refuses Aventis bid for broader use of blood drug
A U.S. federal advisory panel refused to recommend that use of blood-thinning drug be broadly expanded to stave off imminent heart attacks. Aventis Pharmaceuticals Inc.'s Refludan wasn't effective